Instrucțiunile, valorile și ilustrațiile din documentul original sunt păstrate în engleză. Titlul și navigarea sunt în română.
Pagina 1
Pagina 2
Textul documentului original
Pagina 1 — text în engleză
Updated Thyroid I-131 Scan 9/8/2024 ●Indications To assess for the presence of and localization of any functioning residual, recurrent, or metastatic differentiated thyroid carcinoma after thyroidectomy or before/after I-131 ablation and for surveillance. ●Radiopharmaceutical: Diagnostic Imaging - 1-4 mCi I-131 sodium iodine capsule administered by mouth Hyperthyroidism Ablation - 5-15 mCi I-131 sodium iodine capsule administered by mouth Thyroid Cancer Therapy - 30-150 mCi I-131 sodium iodine capsule administered by mouth ●Patient Preparation: No specific preparation prior to radionuclide administration. ●Conflicting Examinations/Medications: The following substances should be withheld for the indicated time frames as they can interfere with the uptake of radioiodine: ◦levothyroxine (Synthroid) - 4 wks ◦amiodarone - 3-6 mths ◦liothyronine (Cytomel) - 2 wks ◦iodine-containing medication/preparation - 4 wks ◦methimazole (Thiamazole) - 3-7 days ◦Lugol's / SSKI solution - 4-6 wks ◦carbimazole - 3-7 days ◦perchlorate - 1 wk ◦propylthiouracil (PTU) - 3-7 days ◦kelp - 4 wks Iodinated IV contrast musted be avoided for 3-4 wks. A low-iodine diet should be followed for 1-2 weeks. Diet adequacy can be confirmed with an AM spot urine iodine level. TSH level should be ≥30 mIU/L accomplished by either thyroid hormone withdrawal or rhTSH (Thyrogen) stimulation. A patient may be maintained on T3 until 10–14 days prior to ablation to avoid severely symptomatic hypothyroidism. ●Pregnancy/Lactation: A negative urine pregnancy test is required in potentially-pregnant patients prior to I-131 administration. See Pregnant, Potentially Pregnant and Lactating Patients policy for specifics. Pregnancy should be avoided for 6 mths following I-131 administration. Breast feeding mothers should discontinue breast feeding 6 wks (preferably 3-6 mths) prior to I-131 administration and should not resume breast feeding the current child. Breast feeding can resume with the next child. ●Imaging Technique: Collimator - medium energy high resolution Photopeak - 364 keV 15% window for I-131 Image Preset Counts ◦Whole Body Images - 8-10 cm/min ◦Static Images - 10-20 mins/image Matrix Size - 256 x 1024 (whole body), 256 x 256 (static) Zoom - 2.67 Patient Positioning - supine ●Imaging Views: Imaging is obtained at 24 hrs and 48-72 hrs after diagnostic imaging doses and usually at 2-7 days after ablative doses. Obtain anterior and posterior whole body images. Obtain anterior static images centered on the neck (from nasopharynx to upper chest) with chin and sternal markers present. ●Notes: Thyroglobulin (Tg) is used as a tumor marker in differentiated thyroid cancer after total thyroidectomy and radioiodine ablation. Typically a Tg level <1.0 ng/mL indicates remission, while a level >10 ng/mL indicates persistent disease. Tg antibody is a class G immunoglobulin and can also be elevated in recurrent thyroid cancer. Metastatic thyroid cancer has lower density of and poorer functioning of Na-I symporters. TSH elevation over time is important to promote increased RAIU and retention in tumors. rhTSH-stimulated scans failed to detect remnant cancer localized to the thyroid bed in 17% of patients and metastatic disease in 29% in whom it was detected after thyroid hormone withdrawal.
Pagina 2 — text în engleză
thyroid bed in 17% of patients and metastatic disease in 29% in whom it was detected after thyroid hormone withdrawal. Tg elevation after rhTSH stimulation is 3–5 times less than that obtained after thyroid hormone withdrawal, which may result in suboptimal evaluation of post operative / post ablation disease burden. Diagnostic RAI imaging may reveal unexpected iodine-avid metastatic disease in 22%–35% of cases and change management in approximately 30%–50% of cases. Diagnostic RAI imaging is useful in determining the I-131 dose for ablation. Larger doses are usually given for treatment if regional or distant metastases are detected on the pre ablation scan. Only 1% of total thyroidectomies are truly total.
Sinteza existentă în aplicație
Protocol oficial de Medicină Nucleară & Radiologie Nucleară integrat conform standardelor de calitate și radiofarmacie clinică ale MCB Radiology și ghidurilor internaționale SNMMI / EANM.
☢️ MEDICINĂ NUCLEARĂ • Terapeutic / Diagnostic
Procedură diagnostică funcțională și moleculară. Evaluarea fiziologică in vivo a metabolismului tisular utilizând radiotrasori specifici de emisie gama sau pozitroni (PET/SPECT).
Cale de administrare: Intravenoasă, inhalatorie sau orală conform protocolului specific.
Măsuri de radioprotecție: Hidratare abundentă post-procedură pentru favorizarea eliminării urinare a radiofarmaceuticului nefixat. Evitarea contactului prelungit cu femei gravide și copii mici timp de 24 ore.
3. Pregătirea Pacientului
Stimulare TSH obligatorie (TSH > 30 uIU/mL): fie prin sevraj hormonal de levotiroxină 4 săptămâni, fie prin administrare de TSH uman recombinant (Thyrogen). Dietă strictă hipoiodată timp de 14 zile.
4. Protocol Tehnic de Achiziție Imagistică
Scanare corp întreg antero-posterioară la 48-72 ore post-ingestie (diagnostic) sau la 5-7 zile post-terapeutic. Colimator de înaltă energie (HEGP), fotopic la 364 keV.
5. Criterii de Interpretare Diagnostică
Fixare normală fiziologică în mucoasa nazală, glande salivare, stomac, tract urinar. Orice focar focal în afara acestor arii reprezintă metastază sau rest tisular tiroidian.